---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-002091"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:26:49.078009+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Regeneron: FY2022 EYLEA US sales $6.26B (+8%), Q4 $1.50B (-3%); expects $30M IPR&D charge

## Summary
- FY2022 EYLEA US net product sales ~$6.26B (+8% YoY); Q4 2022 ~$1.50B (-3% YoY).
- Q4 EYLEA negatively impacted by short-term shift to off-label compounded Avastin and temporary closure of co-pay assistance fund; reversal beginning per Dec 2022 market data.
- Expects ~$30M IPR&D charge from CytomX collaboration, reducing Q4 2022 GAAP/non-GAAP diluted EPS by ~$0.21.
- Aflibercept 8 mg BLA submitted for wAMD and DME using priority review voucher; potential FDA approval by late August 2023.
- Dupixent approved in 2022 for AD infants (6mo-5yr), EoE, prurigo nodularis; sBLA submitted for CSU in biologic-naïve patients.

## SEC filing metadata
- accession: 0001104659-23-002091
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000110465923002091/0001104659-23-002091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000110465923002091/tm231703d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-002091
- JSON: https://secwatch.observer/filing/0001104659-23-002091.json
- Plain text: https://secwatch.observer/filing/0001104659-23-002091.txt

## Key facts
- Earnings Releases
  REGENERON PHARMACEUTICALS, INC. reported full year 2022 results: revenue approximately $6.26 billion.
  - Period: full year 2022
  - Revenue: approximately $6.26 billion
  - Result: preliminary results
  source text: The presentation includes information regarding the Company’s preliminary (unaudited) U.S. net product sales of EYLEA ® (aflibercept) Injection of approximately $6.26 billion for the full year 2022 (based on preliminary (unaudited) fourth quarter 2022 U.S. net product sales of EYLEA of approximately $1.50 billion).
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465923002091/0001104659-23-002091-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.